MIB1 and atopic eczema: Furthermore, our results suggest that Mib1 is a latent therapeutic target for the regulation of Notch activation in disorders caused by a predominance of Th2 cell-cytokines, such as allergies, asthma, atopic dermatitis, systemic lupus erythematosus, and chronic graft-versus-host disease.